Summary of Trisalus Life Sciences FY Conference Call Company Overview - **Company**: Trisalus Life Sciences (NasdaqGM: TLSI) - **Industry**: Oncology-focused medical technology - **Market Opportunity**: $2.5 billion market in liver embolization procedures, currently growing at over 50% per year [2][24] Core Technology and Innovations - **Technology**: Catheter-based system that enhances drug delivery to tumors while minimizing exposure to normal tissue - **Patent Portfolio**: Over 100 patents, with 20-25 patents filed annually, focusing on pressure modulation for optimal tumor perfusion [3][2] - **Drug Delivery Efficiency**: Achieves 50%-500% more drug delivery to tumors compared to traditional methods [7][8] Clinical and Economic Impact - **Patient Outcomes**: Improved overall survival rates and reduced complications due to targeted drug delivery [8][10] - **Cost Savings**: CMS saves approximately $8,000 per procedure due to reduced hospital readmissions [10][11] - **Reimbursement**: Favorable reimbursement landscape with a proprietary embolization code, enhancing hospital revenue [13][10] Product Portfolio and Market Penetration - **Current Devices**: Two devices launched in 2020 and 2021, with plans to introduce two additional sizes to cater to various vascular anatomies [11][12] - **Market Share**: Currently holds a 9% share in the liver embolization market, with significant growth potential [14] - **Expansion into Other Applications**: Technology is being adapted for uterine fibroids, thyroid nodules, and pancreatic treatments, among others [15][19][20] Future Growth Opportunities - **New Applications**: Exploring embolization procedures for osteoarthritis and other orthopedic conditions, which could significantly change treatment paradigms [22][23] - **Collaborations**: Partnerships with other drug companies to enhance drug delivery systems and improve treatment outcomes [20][21] - **Market Strategy**: Targeting 400 hospitals and 1,000 doctors, focusing on a concentrated market approach [13][14] Financial Outlook - **Growth Guidance**: Current year growth projected at 50%, with future guidance under review [28] - **Cost Management**: Focus on reducing R&D and G&A expenses while maintaining positive Adjusted EBITDA by mid-year [29][30] - **Revenue Performance**: Achieved approximately $12 million in revenue last quarter, with gross margins around 85% [30][31] Additional Insights - **Unique Selling Proposition**: The technology's ability to modulate pressure and flow allows for better treatment outcomes and minimizes complications [6][7] - **Regulatory Strategy**: Plans to gather clinical data to support inclusion in treatment guidelines, which could drive adoption [26][27] This summary encapsulates the key points discussed during the Trisalus Life Sciences FY Conference Call, highlighting the company's innovative technology, market opportunities, and financial outlook.